NASDAQ:ONC BeOne Medicines (ONC) Stock Price, News & Analysis $306.05 +8.09 (+2.72%) As of 08/29/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About BeOne Medicines Stock (NASDAQ:ONC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BeOne Medicines alerts:Sign Up Key Stats Today's Range$306.05▼$314.9050-Day Range$240.99▼$321.3652-Week Range$170.99▼$330.63Volume360,221 shsAverage Volume328,635 shsMarket Capitalization$33.54 billionP/E RatioN/ADividend YieldN/APrice Target$330.89Consensus RatingBuy Company Overview BeOne Medicines is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation cancer immunotherapies. The company’s core focus lies in engineering T-cell engager antibodies designed to recruit and activate a patient’s own immune system against solid tumors. By leveraging a proprietary platform for bispecific antibody design, BeOne Medicines aims to create therapies with enhanced specificity and safety profiles compared with conventional approaches. The company’s pipeline comprises multiple early-stage programs directed at validated tumor-associated antigens. These candidates are advancing through preclinical studies, with plans to initiate first-in-human trials in the near term. BeOne Medicines applies a rational target selection process and modular antibody format to optimize pharmacokinetics and tumor penetration, seeking to address unmet needs in indications that have shown limited response to existing treatments. Guided by a multidisciplinary management team with extensive experience in oncology drug development, BeOne Medicines collaborates with leading academic institutions and contract research organizations to accelerate its programs. The company maintains strategic partnerships to support process development, manufacturing, and regulatory strategy, positioning it to progress its immuno-oncology candidates toward clinical milestones and potential commercialization.AI Generated. May Contain Errors. Read More BeOne Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreONC MarketRank™: BeOne Medicines scored higher than 15% of companies evaluated by MarketBeat, and ranked 898th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingBeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBeOne Medicines has only been the subject of 4 research reports in the past 90 days.Read more about BeOne Medicines' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BeOne Medicines are expected to grow in the coming year, from ($5.82) to $0.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BeOne Medicines is -176.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BeOne Medicines is -176.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBeOne Medicines has a P/B Ratio of 8.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ONC. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeOne Medicines does not currently pay a dividend.Dividend GrowthBeOne Medicines does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ONC. News and Social Media3.1 / 5News Sentiment0.62 News SentimentBeOne Medicines has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.11 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for BeOne Medicines this week, compared to 7 articles on an average week.Search Interest7 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat Follows2 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $57,617,229.00 in company stock.Percentage Held by InsidersOnly 6.62% of the stock of BeOne Medicines is held by insiders.Percentage Held by Institutions48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BeOne Medicines' insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeOne Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONC Stock News HeadlinesInsider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) SVP Sells 11,013 Shares of StockAugust 16, 2025 | insidertrades.comBeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Lai Wang Sells 259 SharesAugust 1, 2025 | insidertrades.comRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors.September 1 at 2:00 AM | Investors Alley (Ad)Analysts Set BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Price Target at $330.89August 30 at 2:01 AM | americanbankingnews.comBeOne Medicines stock rises after positive Phase 1/2 resultsAugust 30 at 2:43 AM | za.investing.comBeOne Medicines stock rises after positive Phase 1/2 resultsAugust 30 at 2:43 AM | in.investing.comBeOne Medicines succeeds in Phase 1/2 study for lymphoma therapyAugust 30 at 2:43 AM | msn.comBeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)August 29 at 6:00 AM | businesswire.comSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? BeOne Medicines' stock was trading at $223.50 at the beginning of 2025. Since then, ONC stock has increased by 36.9% and is now trading at $306.05. How were BeOne Medicines' earnings last quarter? BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) released its earnings results on Wednesday, August, 6th. The company reported $0.84 EPS for the quarter, beating the consensus estimate of $0.48 by $0.36. The company earned $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative trailing twelve-month return on equity of 1.22% and a negative net margin of 3.89%. Who are BeOne Medicines' major shareholders? Top institutional investors of BeOne Medicines include Primecap Management Co. CA (4.64%), Temasek Holdings Private Ltd (0.92%), Marshall Wace LLP (0.43%) and Baird Financial Group Inc. (0.31%). Insiders that own company stock include Lai Wang, Lai Wang, Bros Advisors Lp Baker, Xiaodong Wang, Xiaobin Wu, Titus B Ball, Aaron Rosenberg, John Oyler and Chan Henry Lee. View institutional ownership trends. How do I buy shares of BeOne Medicines? Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/06/2025Today9/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ONC Previous SymbolNASDAQ:ONC CIK1651308 WebN/A Phone13459494123FaxN/AEmployees11,000Year FoundedN/APrice Target and Rating Average Price Target for BeOne Medicines$330.89 High Price Target$365.00 Low Price Target$259.00 Potential Upside/Downside+8.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$644.79 million Net Margins-3.89% Pretax Margin-1.39% Return on Equity-1.22% Return on Assets-0.72% Debt Debt-to-Equity Ratio0.04 Current Ratio1.95 Quick Ratio1.72 Sales & Book Value Annual Sales$3.81 billion Price / Sales8.80 Cash FlowN/A Price / Cash FlowN/A Book Value$34.10 per share Price / Book8.98Miscellaneous Outstanding Shares109,600,000Free Float102,344,000Market Cap$33.54 billion OptionableN/A Beta0.21 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ONC) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.